PMEF
YMAB

Point72 Middle East FZE’s Y-mAbs Therapeutics YMAB Stock Holding History

Point72 Middle East FZE’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,359
Closed -$50.2K – 1374
2023
Q4 		$50.2K Buy
+7,359
New +$42.6K ﹤0.01% 1284
2023
Q1 		– Sell
-2,999
Closed -$14.6K – 2281
2022
Q4 		$14.6K Buy
+2,999
New +$21.8K ﹤0.01% 1684

Other funds holding YMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Middle East FZE's YMAB Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Y-mAbs Therapeutics (YMAB) in Q1 2024, closing a stake of 7,359 shares — an estimated $50.2K sold.

Point72 Middle East FZE first reported a position in YMAB in Q4 2022 and held it in 2 quarters. The position peaked at $50.2K in Q4 2023. 96 funds tracked by Wall St. Rank hold YMAB as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Y-mAbs Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 7,359 Y-mAbs Therapeutics shares in Q1 2024, an estimated $50.2K.
  • Point72 Middle East FZE first reported a position in Y-mAbs Therapeutics in Q4 2022 and held it in 2 quarters.
  • Point72 Middle East FZE's Y-mAbs Therapeutics position peaked at $50.2K in Q4 2023.
  • 96 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.